Effects of Bazedoxifene/Vitamin D Combination Therapy on Serum Vitamin D Levels and Bone Turnover Markers in Postmenopausal Women with Osteopenia: A Randomized Controlled Trial
Open Access
- 31 May 2023
- journal article
- research article
- Published by Korean Society for Bone and Mineral Research in Journal of Bone Metabolism
- Vol. 30 (2) , 189-199
Abstract
Background: This study aimed to evaluate the effectiveness of bazedoxifene/vitamin D combination therapy in preventing osteoporosis in postmenopausal women with osteopenia.Methods: This was an open-label, multicenter randomized-controlled, phase 4 clinical trial. Women between ages of 55 and 70 years in 9 medical tertiary centers in Korea were enrolled and assigned into 2 groups: an experiment group and a control group. The experimental group received bazedoxifene 20 mg/vitamin D 800 IU tablets for 6 months, and the control group received calcium 100 mg/vitamin D 1,000 IU tablets for 6 months.Results: A total of 142 patients (70 in the experimental group and 72 in the control group) were included. The least-square mean±standard error of change in propeptide of type I collagen after 3 months was -6.87±2.56% in the experimental group and 1.22±2.54% in the control group. After 6 months, it was -21.07±2.75% in the experimental group and 1.26±2.71% in the control group. The difference between the 2 groups was -22.33% (p<0.01). The change of C-terminal telopeptide was -12.55±4.05% in the experimental group and 11.02±4.03% in the control group after 3 months. It was -22.0±3.95% and 10.20±3.89, respectively, after 6 months. The difference between the 2 groups was -32.21% (p<0.01) after 6 months. There was no significant difference in adverse events between the 2 groups.Conclusions: The osteoporosis preventive effect and safety of administering bazedoxifene/vitamin D combination pill were confirmed in postmenopausal women who needed osteoporosis prevention.Keywords
Funding Information
- Alvogen Korea
This publication has 39 references indexed in Scilit:
- Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)Journal of Bone and Mineral Research, 2012
- Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidenceJournal of Bone and Mineral Research, 2011
- Effects of bazedoxifene in nonflushing postmenopausal womenMenopause, 2011
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosisBMC Musculoskeletal Disorders, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Dietary Calcium and Serum 25-Hydroxyvitamin D Status in Relation to BMD Among U.S. AdultsJournal of Bone and Mineral Research, 2009
- Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled StudyJournal of Bone and Mineral Research, 2008
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Not all SERMs are created equalMenopause, 2006